Rhythm Pharmaceuticals (RYTM) – Investment Analysts’ Weekly Ratings Changes

Rhythm Pharmaceuticals (NASDAQ: RYTM) has recently received a number of price target changes and ratings updates:

• 8/7/2026 – Rhythm Pharmaceuticals had its price target raised by JPMorgan Chase & Co. from $145.00 to $146.00. They now have an “overweight” rating on the stock.
• 8/5/2026 – Rhythm Pharmaceuticals was given a new $154.00 price target by Canaccord Genuity Group Inc..
• 8/5/2026 – Rhythm Pharmaceuticals had its “market outperform” rating reaffirmed by Citigroup Inc..
• 8/5/2026 – Rhythm Pharmaceuticals was given a new $160.00 price target by National Bank Financial.
• 8/5/2026 – Rhythm Pharmaceuticals had its price target raised by Citigroup Inc. from $142.00 to $143.00. They now have a “buy” rating on the stock.
• 8/5/2026 – Rhythm Pharmaceuticals had its price target raised by Royal Bank Of Canada from $141.00 to $155.00. They now have an “outperform” rating on the stock.
• 8/5/2026 – Rhythm Pharmaceuticals had its price target raised by Citizens Jmp from $155.00 to $160.00. They now have a “market outperform” rating on the stock.
• 7/27/2026 – Rhythm Pharmaceuticals is now covered by JPMorgan Chase & Co.. They set an “overweight” rating and a $145.00 price target on the stock.
• 7/17/2026 – Rhythm Pharmaceuticals had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 7/7/2026 – Rhythm Pharmaceuticals had its price target raised by Royal Bank Of Canada from $137.00 to $141.00. They now have an “outperform” rating on the stock.

Insider Transactions at Rhythm Pharmaceuticals

In related news, EVP Yann Mazabraud sold 57,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $116.15, for a total transaction of $6,620,550.00. Following the completion of the transaction, the executive vice president directly owned 55,655 shares in the company, valued at $6,464,328.25. This represents a 50.60% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Alastair Garfield sold 7,763 shares of the stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $117.57, for a total transaction of $912,695.91. Following the completion of the transaction, the insider directly owned 2,295 shares of the company’s stock, valued at approximately $269,823.15. The trade was a 77.18% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 182,676 shares of company stock valued at $20,754,691. 5.90% of the stock is owned by company insiders.

Rhythm Pharmaceuticals, Inc is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company’s research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.

The company’s lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.